Ingrid Bianca Silva
Research Subjects
Ingrid Bianca Silva has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- João Vicente Braga de Souza
Instituto Nacional de Pesquisas da Amazônia
2 shared publications - Juan Diego Ribeiro de Almeida
Instituto Nacional de Pesquisas da Amazônia, Brasil
2 shared publications - Érica Simplício de Souza
Universidade do Estado do Amazonas, Brasil
2 shared publications - Ani Beatriz Jackisch-Matsuura
Leônidas & Maria Deane Research Center, Oswaldo Cruz Foundation (FIOCRUZ) , Manaus, 69057-070
1 shared publication - Carla Silvana da Silva Santos
Postgraduate Program in Biotechnology and Biosciences Applied to Pharmacy, São Paulo State University (UNESP) , Araraquara,14800-903
1 shared publication - Carlos Daniel Santos de Sousa
Instituto Nacional de Pesquisas da Amazônia
1 shared publication
Latest Publications
- 21 September 2026
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 64 (10)
Baseline fluconazole heteroresistance and risk of relapse within 6 months among patients with neurocryptococcosis in the Brazilian Amazon
Cryptococcosis is a severe systemic mycosis, and relapse may be influenced by fungal subpopulations that survive fluconazole exposure. This retrospective cohort study investigated whether fluconazole minimum inhibitory concentration (MIC) and the heteroresistant (HetR) phenotype of the first available diagnostic cerebrospinal-fluid isolate were associated with recorded relapse within 6 months in 70 patients with neurocryptococcosis from Amazonas, Brazil. One clinical isolate per patient, comprising 64 Cryptococcus neoformans molecular type VNI and 6 Cryptococcus gattii molecular type VGII isolates, was evaluated by broth microdilution and endpoint-based fluconazole heteroresistance level (HFL) testing. Using an operational criterion of HFL/MIC ≥ 8, corresponding to visible growth at least three twofold dilutions above the MIC, 43 of 70 isolates (61.4%) were classified as displaying a HetR phenotype. Six-month follow-up was available for 69 patients. Recorded relapse occurred in 12 of 42 patients infected with HetR isolates (28.6%) and in 4 of 27 patients infected with non-HetR isolates (14.8%). Although relapse was numerically more frequent in the HetR group, the association was not statistically significant (conditional odds ratio, 2.27; exact 95% confidence interval, 0.59–10.96; two-sided Fisher’s exact test, P = .248). The HFL/MIC ratio also did not differ significantly according to recorded relapse status (P = .165). The HetR phenotype of the first available diagnostic isolate, defined operationally in this study as HFL/MIC ≥ 8, was frequent but was not significantly associated with recorded relapse within 6 months in this cohort.
- 21 September 2026
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 64 (10)
Baseline fluconazole heteroresistance and risk of relapse within 6 months among patients with neurocryptococcosis in the Brazilian Amazon
Cryptococcosis is a severe systemic mycosis, and relapse may be influenced by fungal subpopulations that survive fluconazole exposure. This retrospective cohort study investigated whether fluconazole minimum inhibitory concentration (MIC) and the heteroresistant (HetR) phenotype of the first available diagnostic cerebrospinal-fluid isolate were associated with recorded relapse within 6 months in 70 patients with neurocryptococcosis from Amazonas, Brazil. One clinical isolate per patient, comprising 64 Cryptococcus neoformans molecular type VNI and 6 Cryptococcus gattii molecular type VGII isolates, was evaluated by broth microdilution and endpoint-based fluconazole heteroresistance level (HFL) testing. Using an operational criterion of HFL/MIC ≥ 8, corresponding to visible growth at least three twofold dilutions above the MIC, 43 of 70 isolates (61.4%) were classified as displaying a HetR phenotype. Six-month follow-up was available for 69 patients. Recorded relapse occurred in 12 of 42 patients infected with HetR isolates (28.6%) and in 4 of 27 patients infected with non-HetR isolates (14.8%). Although relapse was numerically more frequent in the HetR group, the association was not statistically significant (conditional odds ratio, 2.27; exact 95% confidence interval, 0.59–10.96; two-sided Fisher’s exact test, P = .248). The HFL/MIC ratio also did not differ significantly according to recorded relapse status (P = .165). The HetR phenotype of the first available diagnostic isolate, defined operationally in this study as HFL/MIC ≥ 8, was frequent but was not significantly associated with recorded relapse within 6 months in this cohort.
- Open Access
- 1 January 2026
- Published by Research, Society and Development in Research, Society and Development
- Vol. 15 (1)
Naftoquinonas: Potencial biológico e perspectivas como antifúngicos
As infecções fúngicas representam um problema crescente de saúde pública global, especialmente em razão do número limitado de classes de antifúngicos disponíveis, do surgimento de cepas multirresistentes e da elevada toxicidade associada às terapias atuais. Nesse cenário, as naftoquinonas têm despertado grande interesse como compostos bioativos promissores, apresentando ampla diversidade de atividades farmacológicas. Esta revisão apresenta uma análise abrangente da atividade antifúngica de naftoquinonas semissintéticas frente a diferentes fungos patogênicos de relevância clínica, como Candida spp., Cryptococcus spp., Aspergillus spp. e Sporothrix spp. São discutidas a diversidade química dessas moléculas, as modificações semissintéticas e as relações estrutura–atividade, destacando a influência da posição dos substituintes e das propriedades físico-químicas na eficácia antifúngica. Além disso, são abordados os principais mecanismos de ação propostos, como o ciclo redox, a geração de espécies reativas de oxigênio, a interação com a membrana fúngica, a desregulação do equilíbrio osmótico e a ligação covalente a alvos celulares. A toxicidade e a seletividade das naftoquinonas também são analisadas com base em estudos in vitro e in vivo. De modo geral, as naftoquinonas semissintéticas se mostram estruturas químicas promissoras para o desenvolvimento de novos antifúngicos, com potencial para superar a resistência fúngica e reduzir os efeitos adversos associados às drogas convencionais.
- 1 January 2026
- Published by Research, Society and Development in Research, Society and Development
- Vol. 15 (1)
Open AccessNaftoquinonas: Potencial biológico e perspectivas como antifúngicos
As infecções fúngicas representam um problema crescente de saúde pública global, especialmente em razão do número limitado de classes de antifúngicos disponíveis, do surgimento de cepas multirresistentes e da elevada toxicidade associada às terapias atuais. Nesse cenário, as naftoquinonas têm despertado grande interesse como compostos bioativos promissores, apresentando ampla diversidade de atividades farmacológicas. Esta revisão apresenta uma análise abrangente da atividade antifúngica de naftoquinonas semissintéticas frente a diferentes fungos patogênicos de relevância clínica, como Candida spp., Cryptococcus spp., Aspergillus spp. e Sporothrix spp. São discutidas a diversidade química dessas moléculas, as modificações semissintéticas e as relações estrutura–atividade, destacando a influência da posição dos substituintes e das propriedades físico-químicas na eficácia antifúngica. Além disso, são abordados os principais mecanismos de ação propostos, como o ciclo redox, a geração de espécies reativas de oxigênio, a interação com a membrana fúngica, a desregulação do equilíbrio osmótico e a ligação covalente a alvos celulares. A toxicidade e a seletividade das naftoquinonas também são analisadas com base em estudos in vitro e in vivo. De modo geral, as naftoquinonas semissintéticas se mostram estruturas químicas promissoras para o desenvolvimento de novos antifúngicos, com potencial para superar a resistência fúngica e reduzir os efeitos adversos associados às drogas convencionais.